The Infectious Disease Society of America (IDSA) is asking for more information on the US government's plan for deciding how and where to supply Gilead Sciences' remdesivir to treat COVID-19, as reported in Fidelity.
The FDA last week authorized the drug for emergency use and the federal government began distributing the drug this week.
However, some doctors, particularly those in COVID-19 hotspots such as New York and Boston, have had their requests to obtain the new therapy turned down, according to IDSA president Thomas File.
The IDSA is now calling on the government to explain how it will ensure equitable distribution of remdesivir to states and hospitals based on COVID-19 case and hospitalization rates.
The group said it did not know how many hospitals had so far been authorized to receive remdesivir or how many had been denied.
Gilead last week donated 1.5 million vials of the drug to US hospitals, enough to treat at least 140,000 patients, although the donation "is likely to fall short of demand" for the drug throughout the summer, the IDSA said.
To read more NewsPoints articles, click here.